173 related articles for article (PubMed ID: 38047587)
1. Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models.
Nguele Meke F; Bai Y; Ruiz-Avila D; Carlock C; Ayub J; Miao J; Hu Y; Li Q; Zhang ZY
Cancer Res Commun; 2024 Jan; 4(1):5-17. PubMed ID: 38047587
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase of regenerating liver 2 (PRL2) deficiency impairs Kit signaling and spermatogenesis.
Dong Y; Zhang L; Bai Y; Zhou HM; Campbell AM; Chen H; Yong W; Zhang W; Zeng Q; Shou W; Zhang ZY
J Biol Chem; 2014 Feb; 289(6):3799-810. PubMed ID: 24371141
[TBL] [Abstract][Full Text] [Related]
3. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein.
Dong Y; Zhang L; Zhang S; Bai Y; Chen H; Sun X; Yong W; Li W; Colvin SC; Rhodes SJ; Shou W; Zhang ZY
J Biol Chem; 2012 Sep; 287(38):32172-9. PubMed ID: 22791713
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis.
Li Q; Bai Y; Lyle LT; Yu G; Amarasinghe O; Nguele Meke F; Carlock C; Zhang ZY
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20538-20548. PubMed ID: 32788364
[TBL] [Abstract][Full Text] [Related]
5. PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia.
Carlock C; Bai Y; Paige-Hood A; Li Q; Nguele Meke F; Zhang ZY
JCI Insight; 2023 Oct; 8(19):. PubMed ID: 37665633
[TBL] [Abstract][Full Text] [Related]
6. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
7. Role of phosphatase of regenerating liver 1 (PRL1) in spermatogenesis.
Bai Y; Zhou HM; Zhang L; Dong Y; Zeng Q; Shou W; Zhang ZY
Sci Rep; 2016 Sep; 6():34211. PubMed ID: 27666520
[TBL] [Abstract][Full Text] [Related]
8. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
11. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
12. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Suzuki A; de la Pompa JL; Stambolic V; Elia AJ; Sasaki T; del Barco Barrantes I; Ho A; Wakeham A; Itie A; Khoo W; Fukumoto M; Mak TW
Curr Biol; 1998 Oct; 8(21):1169-78. PubMed ID: 9799734
[TBL] [Abstract][Full Text] [Related]
13. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
Vivanco I; Palaskas N; Tran C; Finn SP; Getz G; Kennedy NJ; Jiao J; Rose J; Xie W; Loda M; Golub T; Mellinghoff IK; Davis RJ; Wu H; Sawyers CL
Cancer Cell; 2007 Jun; 11(6):555-69. PubMed ID: 17560336
[TBL] [Abstract][Full Text] [Related]
14. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
15. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
16. Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.
Strumane K; Song JY; Baas I; Collard JG
Leuk Res; 2008 Jan; 32(1):113-20. PubMed ID: 17521720
[TBL] [Abstract][Full Text] [Related]
17. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
Marsh J; Mukherjee P; Seyfried TN
Clin Cancer Res; 2008 Dec; 14(23):7751-62. PubMed ID: 19047102
[TBL] [Abstract][Full Text] [Related]
18. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
[TBL] [Abstract][Full Text] [Related]
19. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
